CD4 and hepatitis A virus infection: Whereas 12 of 12 CD4+ TEM≥21% patients treated with αPD-1/αCTLA-4 dual therapy developed hepatitis, 3 of 4 CD4+ TEM≥21% patients who received αPD-1 monotherapy remained hepatitis free.